CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 125 enrolled
Drug / intervention
Ibudilast +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01860807
NCT01860807Phase 2Completed

Randomized Trial of Ibudilast for Methamphetamine Dependence

University of California, Los Angeles·interventional·Posted May 23, 2013·Updated Jan 30, 2019

In Brief

A Phase 2 clinical trial evaluating Ibudilast and Placebo for Methamphetamine Dependence and HIV Infection. Completed, enrolled 125 participants across 1 site.

Detailed Summary

The objective of this study is to test the safety and potential efficacy of ibudilast to treat methamphetamine dependence. The study hypotheses are that ibudilast will reduce methamphetamine use and increase treatment retention more than placebo among patients seeking treatment for methamphetamine dependence. As HIV infection is a common complication of methamphetamine dependence, half of the participants will be HIV positive and the study will assess whether ibudilast also improves HIV related outcomes (e.g. medication adherence, CD4 count, risk behaviors).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 23, 2013
Enrollment StartJul 1, 2013
Primary CompletionDec 31, 2017
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 13.1 years ago

Interventions

Ibudilastdrug

Placebodrug